Radiopharmaceutical Deal Benchmarks

Median Upfront

$148M

Range: $69M - $229M

Total Deal Value

$1.5B

Range: $811M - $2.1B

Royalty Rate

10% - 17.5%

Tiered up to 21.5%

Dev Milestones

$531M

Range: $297M - $764M

Model Your Deal

Market Analysis

Radiopharmaceuticals have emerged as one of the fastest-growing modalities in oncology deal-making. Phase 1 radiopharmaceutical deals carry a median total deal value of $1.5B, with upfronts averaging $148M. The significant premium reflects constrained supply of radioisotopes, specialized manufacturing requirements, and the theranostic potential that enables patient selection via companion diagnostics.

The milestone structure for radiopharmaceutical deals allocates $531M to development milestones, recognizing the significant de-risking needed around dosimetry, manufacturing scale-up, and supply chain security for isotopes such as actinium-225 and lutetium-177. Commercial milestones of $332M reward the blockbuster trajectory demonstrated by approved RPTs.

Royalty rates range from 10% to 17.5%, with high-tier escalation to 21.5%. The constrained competitive landscape and high barriers to entry for radiopharmaceutical manufacturing give licensors strong negotiating leverage in these transactions.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

Why are radiopharmaceutical deals so highly valued?

Radiopharmaceutical deals command premium valuations ($1.5B median total value at Phase 1) due to constrained isotope supply, specialized manufacturing barriers, theranostic patient selection advantages, and demonstrated blockbuster potential from approved agents like Pluvicto.

What are the key risk factors in radiopharmaceutical licensing?

Primary risk factors include isotope supply security (particularly for alpha emitters), manufacturing scalability, dosimetry optimization, and regulatory pathway complexity for combination radioligand therapies. These risks are reflected in the milestone-heavy deal structures.

How do radiopharmaceutical royalty rates compare to other modalities?

Base royalty rates of 10%-17.5% for RPTs are at the higher end of oncology modalities, reflecting high barriers to entry and limited competition. The manufacturing complexity and isotope supply constraints give licensors significant leverage.

What milestone structure is typical for RPT deals?

RPT deals allocate roughly 90% to milestones. Development milestones ($531M) dominate the structure, with additional regulatory ($464M) and commercial ($332M) payments.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Radiopharmaceutical Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Small Molecule Deals

Phase 2 Deal Benchmarks

Preclinical Deal Benchmarks

Oncology Deal Overview 2026

Ready to Calculate Your Deal Terms?